11:43 AM EST - Stem Cell Therapeutics Corp. : announced it will be providing an update on its SIRPaFc immune checkpoint inhibitor program, targeting the CD47 protein, at the 105th Annual Meeting of the American Association for Cancer Research. The meeting will be held April 5-9, 2014 in San Diego. Stem Cell Therapeutics Corp.
shares V.SSS are trading unchanged at $0.50.
